Abstract:figure legend Loss of plakophilin2 (PKP2) in the mouse atrium leads to impaired cell–cell contact and extensive fibrotic remodelling (middle). PKP2‐deficient atrial cardiomyocytes exhibit enhanced sarcomere shortening and impaired relaxation, potentially related to reduced abundance of myosin binding protein C (left). In addition, PKP2‐deficient atrial cardiomyocytes present increased spontaneous sarcoplasmic reticulum (SR) calcium (Ca2+) release events, further enhanced by isoproterenol exposure and reversible by a ryanodine receptor (RyR) blocker (dantrolene). SR Ca2+ leak is probably caused by elevated levels of oxidative stress (ROS) in the mitochondria (right). Atrial arrhythmias occur in 20–40% of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) and are associated with an increased risk of sustained ventricular arrhythmias and inappropriate implantable cardioverter‐defibrillator shocks. The pathophysiology of atrial arrhythmias in ARVC remains unclear. Most cases of gene‐positive ARVC are linked to pathogenic variants in the desmosomal gene plakophilin‐2 (PKP2). Here, we test the hypothesis that loss of PKP2 expression leads to pro‐arrhythmic changes in atrial cardiomyocytes. Atrial cells/tissue were obtained from a cardiac‐specific, tamoxifen‐activated model of PKP2 deficiency (PKP2cKO). By contrast to PKP2cKO ventricular myocytes, PKP2cKO atrial cardiomyocytes presented no significant differences in intracellular calcium (Ca2+i) transient dynamics, sarcoplasmic reticulum load or action potential morphology. PKP2cKO atrial cardiomyocytes showed elevated reactive oxygen species levels, increased frequency and amplitude of Ca2+ sparks, and increased diastolic [Ca2+]i compared to control; the latter two parameters were further increased by isoproterenol exposure and reversed by exposure to ryanodine receptor blocker dantrolene. We speculate that these isoproterenol‐dependent effects may impact on the exercise‐related atrial arrhythmia risk in ARVC patients. Despite absence of changes in Ca2+i transient dynamics, PKP2cKO atrial cardiomyocytes showed enhanced sarcomere shortening and impaired sarcomere relaxation. Orthogonal transcriptomic analysis of human(GTEx) and PKP2cKO atrial tissue led to identification of 41 transcripts depending on PKP2 expression. Biochemical follow‐up confirmed reduced abundance of sarcomeric protein myosin binding protein C, potentially playing a role in cellular shortening and relaxation changes observed. Our findings provide novel insights into the role of PKP2 in atrial myocardium with potential implications to therapeutic management of atrial fibrillation in patients with PKP2‐related ARVC. Key points Atrial arrhythmias occur in a large group of patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), a cardiac disease mostly caused by pathogenic variants in the desmosomal gene plakophilin‐2 (PKP2). Exercise is considered to be an independent risk factor for arrhythmias consequent to PKP2 deficiency. We show that loss of PKP2 expression affects cellular calcium handling and electrophysiology differently in left atrial vs. ventricular myocardium and causes extensive atrial fibrosis. PKP2‐deficient atrial cardiomyocytes present increased spontaneous sarcoplasmic reticulum calcium release events, further enhanced by isoproterenol exposure and reversible by a ryanodine receptor blocker (dantrolene). In addition, PKP2‐deficient atrial myocytes exhibit impaired relaxation and enhanced sarcomere shortening, most probably related to reduced abundance of myosin binding protein C. We speculate that cellular effects reported upon isoproterenol impact on the exercise‐related atrial arrhythmia risk in ARVC patients. We further propose that therapeutic approaches aimed at mitigating ventricular damage may be effective to treat the atrial disease in ARVC.

Atrial cardiomyopathy resulting from loss of plakophilin‐2 expression: Response to adrenergic stimulation and implications for the exercise response

Leaky RyR2 channels as pro-arrhythmic trigger in the PKP2-deficient atrial myocardium

Characterization of a Novel Mutation in the Cardiac Ryanodine Receptor That Results in Catecholaminergic Polymorphic Ventricular Tachycardia

Functional Consequence of Protein Kinase A-dependent Phosphorylation of the Cardiac Ryanodine Receptor: Sensitization of Store Overload-Induced Ca2+ Release.

Multiomics Analysis Reveals Extensive Remodeling of the Extracellular Matrix and Cellular Metabolism Due to Plakophilin-2 Knockdown in Guinea Pigs

Transcriptomic Coupling of PKP2 With Inflammatory and Immune Pathways Endogenous to Adult Cardiac Myocytes

Cardiac Deficiency of P21-activated Kinase 1 Promotes Atrial Arrhythmogenesis in Mice Following Adrenergic Challenge.

Reduced plakoglobin increases the risk of sodium current defects and atrial conduction abnormalities in response to androgenic anabolic steroid abuse

Computational Modeling of Effects of PKP2 Gene Therapy on Ventricular Conduction Properties in Arrhythmogenic Cardiomyopathy

Abstract P2135: A Novel Pkp2 Mouse Model of Genetic Arrhythmogenic Right Ventricular Cardiomyopathy and Its Rescue by Gene Therapy

Plakophilin 2 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics

Loss of protein phosphatase 2A regulatory subunit PPP2R5A is associated with increased incidence of stress-induced proarrhythmia

Function of A Novel Plakophilin-2 Mutation in the Abnormal Expression of Connexin43 in A Patient with Arrhythmogenic Right Ventricular Cardiomyopathy

AAV-Mediated Delivery of Plakophilin-2a Arrests Progression of Arrhythmogenic Right Ventricular Cardiomyopathy in Murine Hearts: Preclinical Evidence Supporting Gene Therapy in Humans

Abstract 495: The Loss Of Pka Activity And Activation In Cardiomyocytes Does Not Induce Cardiac Abnormalities

Plakophilin-2 truncating variants impair cardiac contractility by disrupting sarcomere stability and organization

Mutations of plakophilin-2 in Chinese with arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Cardiomyocyte PKA Ablation Enhances Basal Contractility While Eliminates Cardiac β-Adrenergic Response Without Adverse Effects on the Heart.

Adipocyte-Mediated Electrophysiological Remodeling of PKP-2 Mutant Human Pluripotent Stem Cell-Derived Cardiomyocytes

Cardiomyocyte PKA ablation eliminates cardiac β-adrenergic response without adverse effects on the heart

Genetic Inhibition of Mitochondrial Permeability Transition Pore Exacerbates Ryanodine Receptor 2 Dysfunction in Arrhythmic Disease